Navigation Links
SCOLR Pharma, Inc. Signs Agreement with The Emerson Group to Provide Sales Support for Nutritional & OTC Products
Date:8/30/2010

BOTHELL, Wash., Aug. 30 /PRNewswire-FirstCall/ -- SCOLR Pharma, Inc. (NYSE AMEX: DDD) today announced that it has signed an agreement with The Emerson Group to provide sales support for the Company's new line of extended-release nutritional and over-the-counter drug products.

The Emerson Group (www.emersongroup.com), headquartered in Wayne, Pa., is a consumer products equity organization that provides strategic consulting and sales execution services to companies in the United States market. 

The Emerson Group will provide strategy consulting, sales, distribution, logistics and account management services in support of SCOLR's new line of extended-release nutritional and over-the-counter drug products, which utilize the Company's proprietary controlled delivery technology®.

Stephen J. Turner, SCOLR Pharma's President and CEO, said, "The Emerson Group has experience with virtually every over-the-counter category and a well established record of success in building overall sales and visibility with retailers. We look forward to the addition of this capability as we grow our consumer products business."

About SCOLR Pharma:Based in Bothell, Washington, SCOLR Pharma, Inc. is a specialty pharmaceutical company focused on applying its formulation expertise and patented CDT platforms to develop novel prescription pharmaceutical, over-the-counter (OTC), and nutritional products. Our CDT drug delivery platforms are based on multiple issued and pending patents and other intellectual property for the programmed release or enhanced performance of active pharmaceutical ingredients and nutritional products. For more information on SCOLR Pharma, please call 425-368-1050 or visit http://www.scolr.com/.

This press release contains forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995, including statements concerning anticipated sales of our nutritional and over-the-counter drug products and the contributions to our business anticipated to be made by our new outsourced services provider.  These forward-looking statements involve risks and uncertainties, including activities, events or developments that we expect, believe or anticipate will or may occur in the future. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including constraints on our liquidity and cash flow related to the greater working capital requirements of our nutritional business and certain provisions of our outsourced services agreements, unanticipated changes in the timing or amount of orders for our nutritional products, greater than anticipated returns of our products by our retail customers, the inability of our outsourced services provider to perform the services required under our agreements or to sell our products to retail customers on favorable terms, and difficulties in competing for retail share with larger, more established and better funded companies.  For example, if our products do not sell through our retail customers at a fast enough rate, we may be required to reserve cash to cover possible retail returns of our products.  Any such obligation may lead us to experience slower cash flow and liquidity constraints.  Absent additional financing, partnership support or additional revenues, we may be forced to cease or curtail our operations. Additional assumptions, risks and uncertainties are described in detail in our registration statements, reports and other filings with the Securities and Exchange Commission, including the "Risk Factors" set forth in our Annual Report on Form 10-K, as supplemented by our quarterly reports on Form 10-Q. Such filings are available on our website or at www.sec.gov. You are cautioned that such statements are not guarantees of future performance and that actual result or developments may differ materially from those set forth in the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstance.Contacts:Investor Relations: SCOLR Pharma, Inc. 425.368.1050
'/>"/>

SOURCE SCOLR Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. SCOLR Pharma, Inc. Enters into Worldwide Licensing Agreement with RedHill Biopharma Ltd.
2. SCOLR Pharma, Inc. Licenses Dietary Supplements
3. SCOLR Pharma, Inc. Receives Notices From NYSE Amex LLC Regarding Compliance Plan and Listing Standards
4. SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results
5. SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results
6. SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen
7. Horizon Pharma, Inc. Files Registration Statement for Proposed Initial Public Offering
8. Horizon Pharma, Inc. Announces Results of Phase 3 Study of LODOTRA® Demonstrate 12-Month Sustained Efficacy and Safety in Rheumatoid Arthritis
9. Horizon Pharma, Inc. Announces FDA Acceptance of DUEXA(R) New Drug Application for Filing
10. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Receives New Research Grant From Hong Kong Innovation and Technology Commission
11. Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... --  Intarcia Therapeutics, Inc. today announced the appointment ... newly created role of Vice President, Head of Global ... decades of leadership experience at leading pharmaceutical, biotechnology, and ... center. Most recently Dr. Yee served as VP, Head ... Medical Officer at AstraZeneca, where he led medical affairs ...
(Date:2/8/2016)... 8, 2016 /PRNewswire/--  Cell Applications, Inc. and ... services are now available in North ... (3D) bioprinting approach called the "Kenzan Method." Utilizing ... a state-of-the-art robotic system that fabricates 3D tissue ... pay-for-service bio-printing model that makes scaffold-free tissue available ...
(Date:2/8/2016)... -- Velano Vascular, a medical technology company transforming and ... practitioners, announced today that the company has raised an ... proceeds from this financing, an extension of a $5 ... support the development and commercialization of the company,s inpatient ... Philadelphia , and a number of ...
Breaking Medicine Technology:
(Date:2/8/2016)... Francisco, CA (PRWEB) , ... February 08, 2016 , ... ... raise $792,000 to help combat pancreatic cancer. , Gary D. Radine, who recently retired ... also was the American Cancer Society’s 2015 CEO of the Year , helped ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... of organizations. DocuSyst provides a cloud hosted environment for FileHold software that ... integration with various 3rd party applications using the FileHold web services API. DocuSyst ...
(Date:2/8/2016)... ... February 08, 2016 , ... TopConsumerReviews.com recently awarded their ... removal products. , Moles are derived from a cluster of melanin when exposed to ... wrong places and create a lifetime of embarrassment. Historically, mole removal has ...
(Date:2/8/2016)... ... February 08, 2016 , ... According to ... the U.S. require dental technicians to be certified or obtain continuing education. To ... created the “What’s In Your Mouth?” campaign to inform dentists and patients about ...
(Date:2/7/2016)... ... February 07, 2016 , ... ... has added Kybella® to his medical and surgical expertise. Technically known as deoxycholic ... injectable medication used as a non-surgical alternative for reduction of fat below the ...
Breaking Medicine News(10 mins):